Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

In Vitro Drug Release Testing: Overview, Development and Validation

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...

Clinically Relevant Drug Product Specifications: Methods of Establishment

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Antibody-mediated rejection of transplanted kidney associated with anti-Jka alloantibodies: An interesting case report with review of literature.

Asian journal of transfusion science·2026

Same author

Editorial Commentary: Look Out for Internal Rotational Tibial Subluxation on Magnetic Resonance Imaging as an Indicator of High-Grade Rotatory Instability in Anterior Cruciate Ligament-Deficient Knees.

Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association·2026

Same author

Correction: Testis-specific serine/threonine kinase 3 regulates the size of sperm reservoir in Anopheles stephensi.

Molecular genetics and genomics : MGG·2025

Same author

Testis-specific serine/threonine kinase 3 regulates the size of sperm reservoir in Anopheles stephensi.

Molecular genetics and genomics : MGG·2025

Same author

Tracheal atresia with associated congenital abnormalities: Two rare cases with multispecialty team work and challenging diagnosis, review of literature.

Indian journal of pathology & microbiology·2025

Same author

Evaluation of Scar Cosmesis and Quality of Life After Thyroid Surgery: A Retrospective Study.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India·2025

Search research articles

Related Experiment Video

Updated: Jun 29, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable

Vishal Saxena¹, Riccardo Panicucci, Yatindra Joshi

¹Technical Research and Development, Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.

Journal of Pharmaceutical Sciences

|October 16, 2008

Summary

The Developability Assessment Group (DAG) aids pharmaceutical R&D by screening and assessing new molecular entities (NMEs). Early collaboration with DAG reduces late-stage attrition, costs, and timelines for drug candidates.

More Related Videos

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Related Experiment Videos

Last Updated: Jun 29, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Area of Science:

Pharmaceutical Research and Development
Drug Discovery and Development
Medicinal Chemistry

Background:

The Developability Assessment Group (DAG) is a critical subgroup in pharmaceutical Research and Development (R&D).
DAG supports scientists in screening, assessing, and selecting New Molecular Entities (NMEs) for clinical studies.
Effective collaboration between discovery teams and DAG is vital for successful drug development.

Purpose of the Study:

To describe the role and responsibilities of the DAG in pharmaceutical R&D.
To highlight the importance of DAG's investigations in NME selection and developability assessment.
To discuss the impact of advanced tools, technologies, and data utilization in the decision-making process.

Main Methods:

Physicochemical and biopharmaceutical characterization of NMEs.
Development of formulations for pharmacokinetic, efficacy, and toxicity studies.
Selection of optimal physical forms (salts, polymorphs) and formulation development for early clinical phases.

Main Results:

DAG activities streamline efficacy-toxicology evaluations.
Developability screens are established to identify promising drug candidates.
Reduced NME attrition rates in late-stage development are achieved through DAG's support.

Conclusions:

Strong collaboration between discovery and DAG is essential for selecting viable NMEs.
DAG's comprehensive assessments decrease drug development costs and timelines.
DAG's work ensures that pharmacologically effective, safe, and developable candidates progress to market.